Category: Press Release

Download PDF – Data presented during poster session at the AACR 2019 Annual Meeting – CAMBRIDGE, Mass.–(BUSINESS WIRE)–Apr. 1, 2019– AVEO Oncology (NASDAQ:AVEO) and Biodesix, Inc. today announced results from an investigator-sponsored Phase Ib expansion cohort of ficlatuzumab, AVEO’s potent hepatocyte growth factor (HGF) inhibitory antibody product candidate, in combination with cytarabine in patients with relapsed and refractory acute

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Mar. 14, 2019– AVEO Oncology (NASDAQ: AVEO) today reported financial results for the full year ended December 31, 2018 and provided a business update. “The results of TIVO-3, presented in February at the 2019 ASCO GU Symposium, underscore a unique activity and tolerability profile among VEGF TKIs in the treatment of kidney cancer,” said Michael Bailey, president and

Download PDF – John H. Johnson to Step Down from Board; Will Remain an Advisor to the Company – CAMBRIDGE, Mass.–(BUSINESS WIRE)–Feb. 26, 2019– AVEO Oncology (NASDAQ: AVEO) today announced the appointment of Gregory T. Mayes to its Board of Directors. Mr. Mayes brings to the AVEO Board over 20 years of experience as a biopharmaceutical executive with deep expertise in business

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Feb. 20, 2019– AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the 8th Annual SVB Leerink Global Healthcare Conference in New York on Wednesday, February 27, 2019 at 2:30 p.m. Eastern Time. A live webcast of the presentation can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. A replay

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Feb. 16, 2019– AVEO Oncology (NASDAQ:AVEO) today announced the presentation of data from the Phase 3 TIVO-3 study of tivozanib (FOTIVDA®) versus sorafenib in refractory advanced or metastatic renal cell carcinoma (RCC). The data were presented by Brian Rini, MD, Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, and Director,

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jan. 31, 2019– AVEO Oncology (NASDAQ: AVEO) today announced that it has accepted the recommendation of the U.S. Food and Drug Administration (FDA) not to submit a New Drug Application (NDA) for tivozanib (FOTIVDA®) with the preliminary overall survival (OS) results from the Phase 3 TIVO-3 trial. The FDA indicated that these preliminary OS results do not allay their

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jan. 2, 2019– AVEO Oncology (NASDAQ: AVEO) today announced that data from the Phase 3 TIVO-3 study of tivozanib (FOTIVDA®) versus sorafenib in refractory advanced or metastatic renal cell carcinoma (RCC) will be presented during an oral session at the 2019 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium being held February 14-16, 2019 in San Francisco. Presentation

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jan. 2, 2019– AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 9, 2019 at 4:00 p.m. Pacific Time. A live webcast of the presentation can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. A replay of

Download PDF Phase 1/2 Study will Evaluate Combination of IMFINZI® (durvalumab) and FOTIVDA® (tivozanib) in First-Line HCC CAMBRIDGE, Mass.–(BUSINESS WIRE)–Dec. 12, 2018– AVEO Oncology (NASDAQ: AVEO) today announced that it has entered into a clinical collaboration with AstraZeneca to evaluate the safety and efficacy of AstraZeneca’s IMFINZI® (durvalumab),a human monoclonal antibody directed against programmed death-ligand 1 (PD-L1), in combination with FOTIVDA® (tivozanib), AVEO’s oral, once-daily, potent

Download PDF Extends Cash Runway to Fund Planned Operations into the Third Quarter of 2019 CAMBRIDGE, Mass.–(BUSINESS WIRE)–Dec. 4, 2018– AVEO Oncology (NASDAQ:AVEO) today announced a six-month extension to the interest only period under its existing amended and restated loan and security agreement with Hercules Capital, Inc. (Hercules). The extension was granted as a result of achieving certain predefined